Takeda Ends Development of Another Celiac Disease Drug, Leaving One Major Candidate in Its Pipeline

Celiac.com 09/11/2026 – Takeda has discontinued development of another experimental treatment for celiac disease, narrowing its once-broad drug pipeline for the condition to a single remaining phase two candidate. The decision affects TAK-101, an immune-focused therapy designed to teach the body to tolerate gliadin, one of the main protein components of gluten.

The setback is disappointing for people hoping for a treatment that could reduce the immune reaction caused by accidental gluten exposure. However, it does not mean that celiac disease drug research has stopped or that the underlying treatment strategy has been disproven. It does show how difficult it is to create a therapy that can safely and reliably change the immune response to gluten.

What Was TAK-101?

Celiac.com Sponsor (A12):


TAK-101 was an experimental treatment built around microscopic particles containing gliadin. Rather than breaking gluten apart in the digestive tract, the therapy was designed to change how the immune system responded to it.

In celiac disease, gluten exposure activates immune cells that contribute to inflammation and damage in the lining of the small intestine. TAK-101 was intended to deliver gliadin to the immune system in a way that encouraged tolerance instead of an inflammatory attack.

This approach was particularly ambitious because it aimed at the autoimmune process itself. If successful, an immune-tolerance therapy might someday reduce the body’s harmful reaction to small amounts of gluten rather than simply treating symptoms after exposure.

Takeda acquired development rights to the treatment from Cour Pharmaceuticals in 2019. Earlier research had produced encouraging signs that the therapy could reduce certain inflammatory immune signals. Takeda later advanced it into a phase two study involving 101 people with celiac disease.

Why Did Takeda Stop the Program?

Takeda stated that development was discontinued following an assessment of the program and the information available to the company. Detailed results from the completed phase two trial were not included in the announcement.

As a result, it is not yet publicly clear whether the decision was driven by insufficient effectiveness, safety concerns, commercial considerations, difficulties with the study design, or a combination of factors. Pharmaceutical companies commonly review all available evidence after a trial and may stop a program if the results do not appear strong enough to justify larger and more expensive studies.

The study was designed to examine whether TAK-101 could reduce gluten-related symptoms and immune activation. The trial concluded earlier in 2026, but the complete findings had not been publicly released at the time Takeda removed the treatment from its active pipeline.

Until more information becomes available, it would be premature to conclude that immune-tolerance treatments cannot work. The failure of one candidate may reflect the specific formulation, dose, delivery method, treatment schedule, patient group, or outcome measures used in that program.

Takeda Has Now Dropped Two Celiac Disease Treatments

TAK-101 is not the first celiac disease therapy Takeda has recently abandoned. The company previously ended development of zamaglutenase, also known as TAK-062.

Zamaglutenase used a very different strategy. It was an engineered enzyme intended to break down gluten in the stomach before harmful fragments could reach the small intestine. Takeda obtained the treatment through its acquisition of PvP Biologics.

The loss of both candidates is significant because the two treatments represented separate approaches to the same problem. One attempted to digest gluten, while the other tried to retrain the immune system. The discontinuations illustrate that promising laboratory science does not always translate into a practical treatment that performs well in clinical trials.

Developing a celiac disease drug is especially challenging because gluten exposure varies greatly from person to person. Symptoms may not closely match the amount of intestinal damage, and trial participants may differ in how strictly they follow the gluten-free diet, how much accidental exposure they experience, and how strongly their immune systems respond.

One Takeda Celiac Disease Drug Remains

Takeda still has one phase two celiac disease candidate in development. The treatment, known as TAK-227 or ZED1227, is an oral drug that blocks tissue transglutaminase 2.

Tissue transglutaminase 2 is an enzyme involved in changing gluten fragments in a way that makes them more likely to trigger the celiac immune response. By inhibiting this enzyme, TAK-227 is designed to interfere with an important step between gluten exposure and immune-driven intestinal injury.

An earlier proof-of-concept study found that the treatment helped protect the lining of the small intestine during a controlled gluten challenge. It was also reported to be generally well tolerated in that study.

The drug is now listed in phase two development, with Dr. Falk Pharma leading the program in partnership with Zedira. Takeda holds development and commercialization rights in the United States and several other regions.

Although the remaining candidate offers continued hope, it is still experimental. A successful early or middle-stage trial does not guarantee regulatory approval. Larger studies must confirm that the treatment provides meaningful benefits, has an acceptable safety profile, and works under real-world conditions.

Why Celiac Disease Treatments Are So Difficult to Develop

Celiac disease may appear to have a straightforward trigger, but the biological process is complicated. A treatment must either prevent gluten from reaching the immune system, block one or more steps in the immune reaction, repair the intestinal barrier, or retrain immune cells without weakening normal immune defenses.

A digestive enzyme must survive stomach acid, remain active during a meal, and destroy enough gluten quickly enough to prevent harmful fragments from reaching the small intestine. An immune-based therapy must reduce the response to gluten without causing broader immune suppression or triggering unintended reactions.

Clinical trials also need reliable ways to measure success. A patient may report fewer symptoms while still having intestinal inflammation. Another patient may have improved biopsy results without noticing a major change in daily symptoms. Researchers may therefore need to evaluate symptoms, blood markers, immune activity, gluten exposure, and intestinal biopsies together.

The treatment goal also matters. A drug intended to protect against trace cross-contact faces a different standard from one intended to make deliberate gluten consumption safe. Most experimental treatments are being developed as additions to the gluten-free diet, not replacements for it.

What This Means for People With Celiac Disease

For people with celiac disease, the discontinuation of TAK-101 is a genuine setback because it removes another potential option from a limited clinical pipeline. It is especially disappointing for those who continue to experience symptoms, intestinal damage, anxiety about restaurant meals, or repeated accidental exposure despite careful adherence to the gluten-free diet.

However, the decision does not change current treatment recommendations. A strict gluten-free diet remains the only established way to control celiac disease. No approved medication currently makes it safe to intentionally consume wheat, barley, or rye.

People should also avoid interpreting this news as evidence that all celiac disease drug development is failing. Takeda’s remaining candidate uses a different biological target, and other companies and research groups continue to study enzymes, immune therapies, barrier-protective treatments, vaccines, and drugs that block specific steps in the disease process.

The TAK-101 trial may still contribute valuable information even though the program has ended. Negative or inconclusive results can help researchers identify ineffective doses, unsuitable delivery methods, weak outcome measures, or patient groups that respond differently. Those lessons may guide the design of future treatments.

What This Means for People With Gluten Sensitivity

TAK-101 was developed specifically for celiac disease, not for non-celiac gluten sensitivity. The two conditions may produce some similar symptoms, but they are not considered the same disorder.

Celiac disease involves a defined autoimmune reaction and can damage the small intestine. Non-celiac gluten sensitivity is diagnosed when gluten-related symptoms occur without the typical celiac antibodies, intestinal findings, or wheat allergy. Its underlying causes may differ among individuals and may involve gluten, other wheat components, or fermentable carbohydrates.

Because TAK-101 targeted the celiac immune response to gliadin, its discontinuation has little direct meaning for people whose symptoms are caused by non-celiac gluten sensitivity. It does, however, underline the importance of obtaining an accurate diagnosis before starting a gluten-free diet or assuming that a future celiac medication would apply to every form of gluten-related illness.

The Bigger Picture

Several years ago, Takeda had three experimental celiac disease therapies using three different strategies: gluten digestion, immune tolerance, and inhibition of tissue transglutaminase 2. Two have now been removed from development, leaving only the tissue transglutaminase inhibitor in the company’s active pipeline.

This contraction may look discouraging, but it also reflects the normal filtering process of drug development. Many therapies that appear promising in early research do not produce strong enough results in larger trials. Stopping a weak program can redirect money and scientific effort toward treatments with a better chance of helping patients.

For the celiac community, the most important unanswered question is why TAK-101 was discontinued. Publication of the trial data would help patients, doctors, and researchers understand whether the problem involved effectiveness, safety, trial design, or business strategy.

The Bottom Line

Takeda has ended development of TAK-101, an experimental nanoparticle therapy intended to retrain the immune system’s response to gluten. The company has not yet released enough detail to show exactly why the program was stopped.

The decision follows the earlier discontinuation of Takeda’s gluten-degrading enzyme treatment and leaves TAK-227, an oral inhibitor of tissue transglutaminase 2, as the company’s sole remaining phase two celiac disease candidate.

For people with celiac disease, this is disappointing but not the end of the search for better treatment. The gluten-free diet remains essential, and any future medication would most likely serve as added protection rather than permission to eat gluten freely. The setback highlights both the complexity of celiac disease and the continuing need for treatments that can reduce intestinal damage, symptoms, and the daily burden of accidental gluten exposure.

Read more at: fiercebiotech.com and clinicaltrials.takeda.com